Hu, Guangzhen
Phillips, Jessica L.
Dasari, Surendra
Jacobs, Hailey K.
Luchtel, Rebecca A.
Oishi, Naoki http://orcid.org/0000-0002-9365-1093
Hundal, Tanya
Ahmed, Nada H.
Satou, Akira
Epstein, Alan L.
Bennani, N. Nora
Nowakowski, Grzegorz S.
Murray, Joseph A.
Feldman, Andrew L. http://orcid.org/0000-0001-5009-4808
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA177734, P30 CA15083, P50 CA97274)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Leukemia and Lymphoma Society (6574-19)
Article History
Received: 10 May 2019
Revised: 7 November 2019
Accepted: 29 November 2019
First Online: 13 December 2019
Compliance with ethical standards
:
: GSN has consulted for Celgene, MorphoSys, Bayer, AbbVie, Janssen, Selvita, Karyopharm Therapeutics, and Soreno, and has received research support from Curis, Roche, Celgene, MorphoSys, and NanoString. ALF has received research support from Seattle Genetics. The remaining authors have no competing financial interests to declare.